WUXI BIOLOGICS (CAYMAN) INC financial statements, including revenue, expenses, and profit
The total revenue of 2269 for the last semiannual is 10.96 B HKD, and it's 17.94% higher compared to the previous semiannual. The net income of H2 24 is 2.01 B HKD.